BACKGROUNDTriple-negative breast cancer (TNBC) is very aggressive with a heightened metastatic incidence as compared to other breast cancer subtypes. However, due to absence of clinically trustworthy biomarkers and specific therapy in TNBC, results are suboptimal. That's why, There's an urge